LPA and atherosclerosis: While we eagerly anticipate the results of large-scale randomized controlled trials investigating the impact of specific Lp(a)-lowering therapies on the risk of MACEs in patients with ASCVD, including Lp(a)HORIZON on pelacarsen (NCT04023552) and OCEAN(a) on olpasiran (NCT05581303), an extra reduction in LDL-C could be considered to mitigate the residual risk associated with an elevation in Lp(a) at different ages (69).